White, M., Bristow, M. R., Anand, I. S., Gottlieb, S. S., Lindenfeld, J., O’Connor, C., … Carson, P. (2007). Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 ARG/GLY receptor polymorphism. In CANADIAN JOURNAL OF CARDIOLOGY (Vol. 23, pp. 169C-169C). PULSUS GROUP INC.

White, M., M. R. Bristow, I. S. Anand, S. S. Gottlieb, J. Lindenfeld, C. O’Connor, A. Miller, et al. “Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 ARG/GLY receptor polymorphism.” In CANADIAN JOURNAL OF CARDIOLOGY, 23:169C-169C. PULSUS GROUP INC, 2007.

White M, Bristow MR, Anand IS, Gottlieb SS, Lindenfeld J, O’Connor C, et al. Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 ARG/GLY receptor polymorphism. In: CANADIAN JOURNAL OF CARDIOLOGY. PULSUS GROUP INC; 2007. p. 169C-169C.

White, M., et al. “Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 ARG/GLY receptor polymorphism.” CANADIAN JOURNAL OF CARDIOLOGY, vol. 23, PULSUS GROUP INC, 2007, pp. 169C-169C.

White M, Bristow MR, Anand IS, Gottlieb SS, Lindenfeld J, O’Connor C, Miller A, Plehn J, Silver MA, Fiuzat M, Robertson AD, Carson P. Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 ARG/GLY receptor polymorphism. CANADIAN JOURNAL OF CARDIOLOGY. PULSUS GROUP INC; 2007. p. 169C-169C.